Multi-omics integration and in vitro validation identify IL4R, IMPA2, and PRR4 as key therapeutic targets in chronic rhinosinusitis with nasal polyps - Scorecard - MDSpire

Multi-omics integration and in vitro validation identify IL4R, IMPA2, and PRR4 as key therapeutic targets in chronic rhinosinusitis with nasal polyps

  • By

  • Bo Wei

  • Weigang Gan

  • Jiaxin Li

  • Feng Wang

  • Jun Wang

  • Binbin Wang

  • Jiaoyu He

  • Feng Liu

  • June 15, 2026

  • 0 min

Share

Clinical Scorecard: Integration of Multi-Omics Data and In Vitro Analysis Reveals IL4R, IMPA2, and PRR4 as Significant Therapeutic Targets in Chronic Rhinosinusitis with Nasal Polyps

At a Glance

CategoryDetail
ConditionChronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Key MechanismsIncreased Th2 cytokines, immune cell infiltration, epithelial barrier dysfunction
Target PopulationIndividuals with Chronic Rhinosinusitis with Nasal Polyps
Care SettingClinical and research settings

Key Highlights

  • Identification of IL4R, IMPA2, and PRR4 as key therapeutic targets
  • Integration of multi-omics data revealed 43 candidate genes
  • Machine learning identified IL4R and IMPA2 as upregulated, PRR4 as downregulated
  • In vitro validation showed modulation of key genes protects against inflammation
  • Potential drugs identified include raloxifene, luteolin, and metronidazole

Guideline-Based Recommendations

Diagnosis

  • Diagnosis primarily relies on symptom assessment, nasal endoscopy, and imaging examinations

Management

  • Treatment includes medical management and surgical options, with biologics for severe cases

Monitoring & Follow-up

  • Monitoring of symptoms and response to treatment is essential

Risks

  • Postoperative recurrence rate for endoscopic sinus surgery is 35-40%

Patient & Prescribing Data

Patients with severe, refractory Chronic Rhinosinusitis with Nasal Polyps

Biologics such as anti-IgE, anti-IL-4/IL-13, and anti-IL-5 antibodies show promising efficacy

Clinical Best Practices

  • Utilize multi-omics integration for understanding molecular mechanisms
  • Consider genetic variations in treatment strategies
  • Implement personalized treatment approaches based on molecular insights

Related Resources & Content

Original Source(s)

Multi-omics integration and in vitro validation identify IL4R, IMPA2, and PRR4 as key therapeutic targets in chronic rhinosinusitis with nasal polyps

  • by Bo Wei, Weigang Gan, Jiaxin Li, Feng Wang, Jun Wang, Binbin Wang, Jiaoyu He, Feng Liu

  • June 15, 2026

Related Content

Nasal Tumor Misdiagnosed as Carcinoma

Accurate histopathologic evaluation and complete excision distinguished a rare benign lesion from squamous cell carcinoma and guided management.

Diagnostic value and immune microenvironment regulatory network of metabolic reprogramming in chronic rhinosinusitis with nasal polyps identified by multidimensional transcriptome integration and machine learning

Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden